\
&
Contact us
\
&
Contact us
This was 2 years ago
LocationParis, France
The network of Health National Contact Points (HNN3.0) is organising a next Brokerage Event dedicated to Horizon Europe Health calls for proposals 2024 for which the involvement of partners with expertise in Social Sciences and Humanities (SSH) is of importance. This event is organised in collaboration with Net4Society, the network of Cluster 2 National Contact Points. The 7 call topics targeted by the event are listed on the event website.
This event is of interest to potential applicants to Horizon Europe Health 2024 calls who are looking for SSH partners and for SSH researchers who want to contribute to health-related projects. The event will include pitch sessions and bilateral meetings for participants to share their ideas and interests in the calls.
More information and registration on the event website. Registration deadline is 30 April 2023. For any further information on the event, please contact the French Health NCP team at: pcn-sante@recherche.gouv.fr
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
